The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Open accessAbstract
Purpose: Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in > 70% of pancreatic cancers (PCs). We investigated the impact of vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in a multicenter phase Ib/randomized phase II trial and preclinical PC models. Patients and Methods: Patients with PC not amenable to curative therapy who had received no prior therapy for metastatic disease and had Karnofsky performance score ≥ 80 were enrolled. Patients were randomly assigned in a one-to-one ratio to GV or GP. The primary end point was progression-free-survival (PFS). Exploratory correlative studies included serial SHH serum levels and contrast perfusion computed tomography imaging. To further investigate putative biologic mechanisms of SMO inhibition, two autochthonous pancreatic cancer models (Kras G12D; p16/p19 fl/fl; Pdx1-Cre and Kras G12D; p53 R270H/wt; Pdx1-Cre) were studied. Results: No safety issues were identified in the phase Ib portion (n = 7), and the phase II study enrolled 106 evaluable patients (n = 53 in each arm). Median PFS was 4.0 and 2.5 months for GV and GP arms, respectively (95% CI, 2.5 to 5.3 and 1.9 to 3.8, respectively; adjusted hazard ratio, 0.81; 95% CI, 0.54 to 1.21; P = .30). Median overall survival (OS) was 6.9 and 6.1 months for GV and GP arms, respectively (95% CI, 5.8 to 8.0 and 5.0 to 8.0, respectively; adjusted hazard ratio, 1.04; 95% CI, 0.69 to 1.58; P = .84). Response rates were not significantly different. There were no significant associations between correlative markers and overall response rate, PFS, or OS. Preclinical trials revealed no significant differences with vismodegib in drug delivery, tumor growth rate, or OS in either model. Conclusion: The addition of vismodegib to gemcitabine in an unselected cohort did not improve overall response rate, PFS, or OS in patients with metastatic PC. Our preclinical and clinical results revealed no statistically significant differences with respect to drug delivery or treatment efficacy using vismodegib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 3. Clinical trial translational correlatives. Serum SHH levels (A) comparing controls (n = 40) with patients with pancreatic cancer enrolled onto trial (n = 89), (B) by treatment group (gemcitabine plus vismodegib [GV] or gemcitabine plus placebo [GP]) with increasing treatment (TX) cycle, and association with age in (C) patients with cancer and (D) controls. (E) Radiologic correlatives evaluating association of baseline tumor perfusion with tumor response to therapy.](/paper-figures/1a65b8774a2c48bf9fb304d7a14b415a/randomized-phase-ib-ii-study-of-gemcitabine-plus-placebo-or-vismodegib-a-figure-3.jpg)
![Fig 5. Smoothened (SMO) inhibitor does not affect tumor progression or overall survival in Kras LSL-G12D; p16/p19 fl/fl; Pdx1-Cre (KPP) mice. (A) Individual tumor growth rates plotted by from serial ultrasound images as volumes depicted longitudinally by animal within each regimen. (B) Antilogged values of slopes in each longitudinal plot are graphed, and average tumor burden fold changes per day in each study group of KPP mice are shown, with approximate 95% CIs (vehicle v SMO inhibitor, P = .86; vehicle v combination, P = .0156; gemcitabine v combination, P = .18) (C) Kaplan-Meier plots of KPP mice treated with vehicle (blue, n = 15; median, 1.9 weeks), SMO inhibitor (gold, n = 16; median, 1.2 weeks), gemcitabine (gray, n = 14; median, 3.8 weeks), and gemcitabine plus SMO inhibitor combination (red, n = 12; median, 3.4 weeks; gemcitabine v vehicle, P = .0059; combination v vehicle, P = .0179; gemcitabine v combination, P = .10 [all P values from log-rank test]). HhAntag, hedgehog pathway antagonism.](/paper-figures/a743673eb55d4afe92010381f297db65/randomized-phase-ib-ii-study-of-gemcitabine-plus-placebo-or-vismodegib-a-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many of the recent promising clinical signals in PDAC have arisen through rigorous preclinical analyses in syngeneic and autochthonous models that predated the trial and informed its design288.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [288]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y., Gysin, S., Castillo, C. F. F.-D., Yajnik, V., et al. (2003) · Nature · doi:10.1038/nature02009 · Cited by 1,479
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Hoff, D. D. V., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,017
A paracrine requirement for hedgehog signalling in cancer
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T. T.-L., Tian, H., Ahn, C. P., Marshall, D. C. L., Fu, L., Januario, T., Kallop, D. Y., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848
Self-citationCutsem, E. V., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Laethem, J. V., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J. G. C. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 651
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 643
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
Morris, J. P., Wang, S. C., & Hebrok, M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2899 · Cited by 597
LoRusso, P. M., Rudin, C. M., Reddy, J. C., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., Chang, I., Darbonne, W. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2745 · Cited by 543
Romer, J. T., Kimura, H., Magdaleno, S. M., Sasai, K., Fuller, C. E., Baines, H., Connelly, M., Stewart, C. F., Gould, S. E., Rubin, L. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.019 · Cited by 521
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffrey, T. C., Ouellette, M. M., & Hollingsworth, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0291 · Cited by 520
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
Tian, H., Callahan, C. A., DuPree, K., Darbonne, W. C., Ahn, C. P., Scales, S. J., & de Sauvage, F. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813203106 · Cited by 416
Hruban, R., Adsay, N., Albores-saavedra, J., Anver, M., Biankin, A., Boivin, G. P., Furth, E., Furukawa, T., Klein, A., Klimstra, D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2168 · Cited by 411
Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Letourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70004-3 · Cited by 402
Self-citationGDC-0449—A potent inhibitor of the hedgehog pathway
Robarge, K. D., Brunton, S. A., Castanedo, G. M., Cui, Y., Dina, M. S., Goldsmith, R. A., Gould, S. E., Guichert, O., Gunzner, J. L., Halladay, J. S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.049 · Cited by 387
Dijkgraaf, G. J. P., Alicke, B., Weinmann, L., Januario, T., West, K. A., Modrusan, Z. D., Burdick, D., Goldsmith, R. A., Robarge, K. D., Sutherlin, D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2876 · Cited by 365
Kim, E. J.-H., Sahai, V., Abel, E. V., Griffith, K. A., Greenson, J. K., Takebe, N., Khan, G. N., Blau, J., Craig, R. A., Balis, U. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1269 · Cited by 307
Self-citationFeldmann, G., Fendrich, V., McGovern, K., Bedja, D., Bisht, S., Alvarez, H., Koorstra, J.-B. M., Habbe, N., Karikari, C. A., Mullendore, M. E., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0573 · Cited by 275
Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)
Tremblay, M. R., Lescarbeau, A., Grogan, M. J., Tan, E., Lin, G., Austad, B. C., Yu, L.-C., Behnke, M. L., Nair, S. J., Hagel, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900305z · Cited by 252
Prasad, N. B., Biankin, A. V., Fukushima, N., Maitra, A., Dhara, S., ELKAHLOUN, A. G., Hruban, R. H., Goggins, M., & Leach, S. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1413 · Cited by 240
Growth inhibition of polyoma transformed cells by contact with static normal fibroblasts
Stoker, M. G. P., Shearer, M., & O'Neill, C. H. (1966) · Journal of Cell Science · doi:10.1242/jcs.1.3.297 · Cited by 216
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Reslan, H. B., Ho, C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 214
Wang, Y., Zhou, Z., Walsh, C. T., & McMahon, A. P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812110106 · Cited by 206
Paracrine Hedgehog Signaling in Cancer
Theunissen, J.-W. F., & de Sauvage, F. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0756 · Cited by 201
Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer
Feldmann, G., Habbe, N., Dhara, S., Bisht, S., Alvarez, H., Fendrich, V., Beaty, R. M., Mullendore, M. E., Karikari, C. A., Bardeesy, N. M., et al. (2008) · Gut · doi:10.1136/gut.2007.148189 · Cited by 193
Walter, K., Omura, N., Hong, S., Griffith, M., Vincent, A., Borges, M. W., & Goggins, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1913 · Cited by 172
Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
Jimeno, A., Weiss, G. J., Miller, W. H., Gettinger, S. N., Eigl, B. J., Chang, A. L. S., Dunbar, J., Devens, S., Faia, K., Skliris, G. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3654 · Cited by 171
Functional computed tomography in oncology
Miles, K. A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00386-6 · Cited by 152
Catenacci, D. V. T. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 143
Self-citationDotto, G. P., Weinberg, R. A., & Ariza, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.17.6389 · Cited by 137
Chen, W., Tang, T. T.-L., Eastham-Anderson, J., Dunlap, D. Y., Alicke, B., Nannini, M., Gould, S. E., Yauch, R. L., Modrusan, Z. D., DuPree, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017945108 · Cited by 122
Hedgehog signaling and therapeutics in pancreatic cancer
Kelleher, F. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq280 · Cited by 114
The Hedgehog Pathway and Pancreatic Cancer
Hidalgo, M. M., & Maitra, A. (2009) · New England Journal of Medicine · doi:10.1056/nejmcibr0905857 · Cited by 110
Kandel, S. M., Kloeters, C., Meyer, H., Hein, P. A., Hilbig, A., & Rogalla, P. (2009) · European Radiology · doi:10.1007/s00330-009-1453-z · Cited by 107
The dawn of hedgehog inhibitors: Vismodegib
Selvarajan, S., Melvin, G., Kumar, S. S., & Dkhar, S. A. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.107628 · Cited by 86
Discovery and preclinical development of vismodegib
Gould, S. E., Low, J. A., Marsters, J. C., Robarge, K. D., Rubin, L. L., de Sauvage, F. J., Sutherlin, D. P., Wong, H., & Yauch, R. L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.920816 · Cited by 72
Hattori, Y., Gabata, T., Matsui, O., Mochizuki, K., Kitagawa, H., Kayahara, M., Ohta, T., & Nakanuma, Y. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3114 · Cited by 58
Wong, H., Chen, J. Z., Chou, B., Halladay, J. S., Kenny, J. R., La, H., Marsters, J. C., Plise, E. G., Rudewicz, P. J., Robarge, K. D., et al. (2009) · Xenobiotica · doi:10.3109/00498250903180289 · Cited by 56
Jesus‐Acosta, A. D., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Maitra, A., Rasheed, Z. A., Zheng, L., Rajeshkumar, N. V., Le, D. T., Hoering, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.257 · Cited by 53
Catenacci, D. V. T., Bahary, N., Nattam, S. R., Marsh, R., Wallace, J. A., Rajdev, L. N., Cohen, D. J., Sleckman, B. G., Lenz, H., Stiff, P. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4012 · Cited by 39
Self-citationAbe, H., Murakami, T., Kubota, M., Kim, T., Hori, M., Kudo, M., Hashimoto, K., Nakamori, S., Dono, K., Tomoda, K., et al. (2005) · PubMed · Cited by 35
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer
Xu, F.-G., Ma, Q., & Wang, Z. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.014 · Cited by 29
Yuki, Y., Hattori, Toshifumi, Gabata, Osamu, Matsui, Kentaro, Mochizuki, Hirohisa, Kitagawa, et al. (2009) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 28
Plasma Shh Levels Reduced in Pancreatic Cancer Patients
Zaatari, M. E., Daignault, S. D., Tessier, A., Kelsey, G., Travnikar, L. A., Cantu, E. F., Lee, J., Plonka, C. M., Simeone, D. M., Anderson, M. A., et al. (2012) · Pancreas · doi:10.1097/mpa.0b013e31824a0eeb · Cited by 15
Research works printed but not linked: 2
- Abe H, 2005, Radiat Med, 23, 364
- Jesus-Acosta A, 2014, J Clin Oncol, 32
Cited by
Sorted by citations
Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,957
Self-citationPancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Diversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265
Metadata
- Authors
- Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., Cohen, D., Wade, J., Sleckman, B., Lenz, H.-J., Stiff, P., Kumar, P., Xu, P., Henderson, L., Takebe, N., Salgia, R., Wang, X., Stadler, W. M., de Sauvage, F. J., & Kindler, H. L.
- Affiliations
- Loyola University Medical Center (US)
- Daniel V.T. Catenacci, Theodore Karrison, James Wallace, Mark Kozloff, Peng Xu, Les Henderson, Ravi Salgia, Walter M. Stadler, Hedy L. Kindler, University of Chicago Medical Center; Patrick Stiff, Loyola University Medical Center, Chicago; Robert Marsh, Northshore University Health System, Evanston; James Wallace, Mark Kozloff, Ingalls Hospital, Harvey; James Wade, Decatur Memorial Hospital, Decatur; Pankaj Kumar, Oncology/Hematology Associates, Peoria, IL; Melissa R. Junttila, Xi Wang, and Frederic J....
- Corresponding author
- Catenacci, Daniel V.T.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2015-12-20
- Volume
- 33
- Issue
- 36
- Pages
- 4284-4292
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC4678179
- OpenAlex
- W2137357003
- Cited by
- 561
- References
- 55
- Citations by year
- 2026: 40 · 2025: 36 · 2024: 38 · 2023: 47 · 2022: 71 · 2021: 72 · 2020: 67 · 2019: 65 · 2018: 60 · 2017: 41 · 2016: 20 · 2015: 3
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- European Society for Medical Oncology
- National Institutes of Health (UL1TR000430, n01cm62201-16-0-1)
- Genentech
- National Cancer Institute (N01 CM062201, N01 CM-62201)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metastatic pancreatic cancer, gemcitabine, vismodegib, sonic hedgehog pathway, Smoothened inhibition, Hedgehog pathway inhibitors, progression-free survival, overall survival, KRAS G12D, p53, drug safety, combination therapy
- MeSH terms
- Gemcitabine, Adult, Aged, Anilides, Animals, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Pyridines, Signal Transduction, Odds Ratio, Treatment Outcome, Karnofsky Performance Status, Disease-Free Survival, Mice, Kaplan-Meier Estimate, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
